LifeMD Q4 revenue rises but misses estimates

Reuters03-10

LifeMD Q4 revenue rises but misses estimates

Overview

Virtual primary care provider's Q4 revenue rose 4% but missed analyst expectations
Adjusted EBITDA for Q4 rose 348%, beating analyst expectations
Company launched oral Wegovy after year-end, boosting weight management patient growth

Outlook

LifeMD expects Q1 2026 revenue between $48 mln and $49 mln
Company anticipates Q1 adjusted EBITDA loss of $4 mln to $5 mln
LifeMD forecasts 2026 revenue between $220 mln and $230 mln

Result Drivers

INFRASTRUCTURE EXPANSION - Co's benefits infrastructure on track to cover 220 million Americans by Q2, supporting women's health growth

Company press release: ID:nGNX8rTbgQ

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Revenue	Miss	$46.9 mln	$48.57 mln (8 Analysts)
Q4 EPS		$0.41
Q4 Adjusted EBITDA	Beat	$4.8 mln	$4.06 mln (7 Analysts)
Q4 Gross Margin		87%

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for LifeMD Inc is $8.50, about 183.3% above its March 6 closing price of $3.00

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618674058?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-10 04:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618674058","market":"fut","top_or_hot":-1,"title":"LifeMD Q4 revenue rises but misses estimates","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>LifeMD Q4 revenue rises but misses estimates</title></head><body><p><span>Overview</span></p><ul><li><p>Virtual primary care provider's Q4 revenue rose 4% but missed analyst expectations</p></li><li><p>Adjusted EBITDA for Q4 rose 348%, beating analyst expectations</p></li><li><p>Company launched oral Wegovy after year-end, boosting weight management patient growth</p></li></ul><p><span>Outlook</span></p><ul><li><p>LifeMD expects Q1 2026 revenue between $48 mln and $49 mln</p></li><li><p>Company anticipates Q1 adjusted EBITDA loss of $4 mln to $5 mln</p></li><li><p>LifeMD forecasts 2026 revenue between $220 mln and $230 mln</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>INFRASTRUCTURE EXPANSION - Co's benefits infrastructure on track to cover 220 million Americans by <a href=\"https://laohu8.com/S/QTWO\">Q2</a>, supporting women's health growth</p></li></ul><p>Company press release: <span>ID:nGNX8rTbgQ</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Revenue</p></td><td><p>Miss</p></td><td><p>$46.9 mln</p></td><td><p>$48.57 mln (8 Analysts)</p></td></tr><tr><td><p>Q4 EPS</p></td><td></td><td><p>$0.41</p></td><td></td></tr><tr><td><p>Q4 Adjusted EBITDA</p></td><td><p>Beat</p></td><td><p>$4.8 mln</p></td><td><p>$4.06 mln (7 Analysts)</p></td></tr><tr><td><p>Q4 Gross Margin</p></td><td></td><td><p>87%</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 7 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the advanced medical equipment &amp; technology peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for LifeMD Inc is $8.50, about 183.3% above its March 6 closing price of $3.00</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LifeMD Q4 revenue rises but misses estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLifeMD Q4 revenue rises but misses estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-10 04:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>LifeMD Q4 revenue rises but misses estimates</title></head><body><p><span>Overview</span></p><ul><li><p>Virtual primary care provider's Q4 revenue rose 4% but missed analyst expectations</p></li><li><p>Adjusted EBITDA for Q4 rose 348%, beating analyst expectations</p></li><li><p>Company launched oral Wegovy after year-end, boosting weight management patient growth</p></li></ul><p><span>Outlook</span></p><ul><li><p>LifeMD expects Q1 2026 revenue between $48 mln and $49 mln</p></li><li><p>Company anticipates Q1 adjusted EBITDA loss of $4 mln to $5 mln</p></li><li><p>LifeMD forecasts 2026 revenue between $220 mln and $230 mln</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>INFRASTRUCTURE EXPANSION - Co's benefits infrastructure on track to cover 220 million Americans by <a href=\"https://laohu8.com/S/QTWO\">Q2</a>, supporting women's health growth</p></li></ul><p>Company press release: <span>ID:nGNX8rTbgQ</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Revenue</p></td><td><p>Miss</p></td><td><p>$46.9 mln</p></td><td><p>$48.57 mln (8 Analysts)</p></td></tr><tr><td><p>Q4 EPS</p></td><td></td><td><p>$0.41</p></td><td></td></tr><tr><td><p>Q4 Adjusted EBITDA</p></td><td><p>Beat</p></td><td><p>$4.8 mln</p></td><td><p>$4.06 mln (7 Analysts)</p></td></tr><tr><td><p>Q4 Gross Margin</p></td><td></td><td><p>87%</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 7 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the advanced medical equipment &amp; technology peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for LifeMD Inc is $8.50, about 183.3% above its March 6 closing price of $3.00</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4167","symbol_name":"医疗保健技术","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nL1N3ZX14J:1","article_id":"2618674058","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618674058","pubTimestamp":1773087841,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"LifeMD Q4 revenue rises but misses estimatesOverviewVirtual primary care provider's Q4 revenue rose 4% but missed analyst expectationsAdjusted EBITDA for Q4 rose 348%, beating analyst expectationsComp","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4167":"医疗保健技术","LFMD":"LifeMD Inc.","BK4183":"个人用品"},"translate_title":"LifeMD第四季度收入增长但未达到预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LFMD":0.9},"content_text":"LifeMD Q4 revenue rises but misses estimatesOverviewVirtual primary care provider's Q4 revenue rose 4% but missed analyst expectationsAdjusted EBITDA for Q4 rose 348%, beating analyst expectationsCompany launched oral Wegovy after year-end, boosting weight management patient growthOutlookLifeMD expects Q1 2026 revenue between $48 mln and $49 mlnCompany anticipates Q1 adjusted EBITDA loss of $4 mln to $5 mlnLifeMD forecasts 2026 revenue between $220 mln and $230 mlnResult DriversINFRASTRUCTURE EXPANSION - Co's benefits infrastructure on track to cover 220 million Americans by Q2, supporting women's health growthCompany press release: ID:nGNX8rTbgQKey DetailsMetricBeat/MissActualConsensus EstimateQ4 RevenueMiss$46.9 mln$48.57 mln (8 Analysts)Q4 EPS$0.41Q4 Adjusted EBITDABeat$4.8 mln$4.06 mln (7 Analysts)Q4 Gross Margin87%Analyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 7 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the advanced medical equipment & technology peer group is \"buy\"Wall Street's median 12-month price target for LifeMD Inc is $8.50, about 183.3% above its March 6 closing price of $3.00For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618674058","isCrawlerRequest":true}